Compare SXTP & AZTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SXTP | AZTR |
|---|---|---|
| Founded | 2010 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6M | 3.5M |
| IPO Year | 2023 | 2023 |
| Metric | SXTP | AZTR |
|---|---|---|
| Price | $1.16 | $0.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $14.10 | $4.00 |
| AVG Volume (30 Days) | 52.4K | ★ 617.7K |
| Earning Date | 05-15-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 36.77 | 5.06 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,005,471.00 | N/A |
| Revenue This Year | $33.92 | N/A |
| Revenue Next Year | $51.35 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 65.49 | N/A |
| 52 Week Low | $0.34 | $0.10 |
| 52 Week High | $8.62 | $1.09 |
| Indicator | SXTP | AZTR |
|---|---|---|
| Relative Strength Index (RSI) | 57.63 | 50.62 |
| Support Level | $1.05 | $0.16 |
| Resistance Level | $1.26 | $0.19 |
| Average True Range (ATR) | 0.10 | 0.01 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 83.34 | 25.99 |
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.
Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.